Targeted therapies in metastatic renal cancer in 2009
- 27 April 2009
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 103 (10) , 1334-1342
Abstract
The development of targeted molecules in renal carcinogenesis changed the therapeutic approaches of treatment for metastatic clear cell renal cell carcinoma. Four available drugs are currently available, i.e. bevacizumab, sunitinib, sorafenib and temsirolimus, but other molecules and combined therapy are under investigation. In this review we assess published reports of these targeted therapies and discuss the novel promising molecules targeting vascular endothelial growth factor and its receptors, the mammalian target of rapamycin and epithelial growth factor cascade.Keywords
This publication has 47 references indexed in Scilit:
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2007
- VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockadeProceedings of the National Academy of Sciences, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a reviewAnnals of Oncology, 2006
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Molecular basis of the VHL hereditary cancer syndromeNature Reviews Cancer, 2002
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Angiogenesis in cancer and other diseasesNature, 2000
- Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 1999